MAIN CONTENT
The board says no
In a statement on October 26, Challenger said the indicative bid from TAL Daiichi Life Australia was not at a level the board could recommend to shareholders. However, it intends to engage with Daiichi Life's Australian unit to see whether a proposal can be reached that the board can recommend, though there is no certainty a binding offer or transaction will materialise.
Last week, TAL Daiichi Life Australia offered to buy the remaining 79.5% of Challenger at A$11.80 a share, valuing the financial firm at about A$7.9 billion ($5.5 billion). Shares of both Challenger and Daiichi Life were little changed on Monday.














